Introduction to Gvoke VialDx™
American Regent, Inc. has recently launched Gvoke VialDx™, a transformative glucagon injection designed to aid in diagnostic procedures. This product introduces the first concentrated, ready-to-dilute liquid glucagon for use in medical settings, enhancing the efficiency of gastrointestinal motility inhibition during crucial radiologic examinations.
What is Gvoke VialDx™?
Gvoke VialDx™ is indicated specifically for intravenous use, functioning as a gastrointestinal motility inhibitor. It aids healthcare professionals during radiologic exams by temporarily halting gastrointestinal motion in adult patients, which is essential for accurate imaging and diagnosis.
Partnership with Xeris Pharmaceuticals
The commercial rollout of Gvoke VialDx is a product of strategic collaboration between American Regent and Xeris Pharmaceuticals, Inc. As part of this partnership, Xeris oversees product supply, while American Regent manages the marketing and distribution in the United States.
Expert Insights
Joann Gioia, the Vice President and Chief Commercial Officer at American Regent, emphasized the importance of this product, stating, “We are eager to leverage our expertise in the hospital and acute care settings to enhance the success of Gvoke VialDx. This product addition helps us fulfill our commitment to providing essential medicines to patients.”
Kevin McCulloch, President and COO of Xeris, proudly highlighted the significance of the launch, explaining, “This liquid glucagon innovation will serve as a vital new option for hospitals and clinics, marking a noteworthy step forward in patient care.”
Product Availability
Gvoke VialDx will be marketed in both a 1-count and a 10-count package, with each vial containing 1 mg per 0.2 mL of the product available for immediate shipment. Healthcare providers can obtain this product through their usual wholesalers and distributors or directly by contacting American Regent’s Customer Support Group at 1-800-645-1706.
Understanding Important Safety Information
As with any pharmaceutical, it is vital to be aware of the safety information related to Gvoke VialDx. Key contraindications include:
- Pheochromocytoma, due to severe hypertension risks.
- Insulinoma, due to the potential for hypoglycemia.
- Prior hypersensitivity reactions to glucagon or any excipients in Gvoke VialDx.
- Glucagonoma, given the risks associated with hypoglycemia.
Warnings and Precautions
Patients with specific health conditions need to exercise caution when using Gvoke VialDx:
- Individuals with pheochromocytoma may experience significant blood pressure increases, necessitating close monitoring.
- In insulinoma cases, administering glucagon might inadvertently lead to hypoglycemia due to exaggerated insulin release.
- Healthcare providers should monitor diabetic patients for potential hyperglycemia while using Gvoke VialDx.
Adverse Reactions and Drug Interactions
Common adverse reactions noted in clinical trials included nausea, headache, and dizziness, occurring in 5% or more of adult volunteer recipients. Additionally, specific drug interactions can affect patient outcomes:
- Patients on beta-blockers may experience transient increases in pulse and blood pressure when given Gvoke VialDx.
- Insulin works antagonistically to glucagon, which could alter blood sugar management.
- Concomitant use of anticholinergic drugs may amplify gastrointestinal adverse effects.
Indications and Usage
Gvoke VialDx is officially indicated for intravenous use as a diagnostic aid to help temporarily restrict gastrointestinal movement during radiology procedures in adult patients. Careful adherence to prescribed indications is essential for achieving optimal patient safety and efficacy when utilizing Gvoke VialDx.
Company Overview
American Regent, Inc., part of the Daiichi Sankyo Group, has established itself as a leader in the injectable manufacturing sector over its more than 50-year history. With an unwavering commitment to quality, American Regent develops a range of generic and branded injectables that enhance patient care and outcomes.
In line with this mission, the company has made significant investments to expand and modernize its manufacturing facilities to better serve healthcare providers and patients. Their commitment to quality ensures that patients have timely access to necessary medications.
Frequently Asked Questions
What is Gvoke VialDx™?
Gvoke VialDx is a glucagon injection used as a temporary gastrointestinal motility inhibitor during radiologic examinations.
Where can healthcare providers obtain Gvoke VialDx™?
Healthcare providers can order Gvoke VialDx through their wholesaler or distributor, or they can contact American Regent's Customer Support Group directly.
What are the common side effects of Gvoke VialDx™?
Common side effects include nausea, headache, and dizziness, reported in a small percentage of patients.
Who should avoid using Gvoke VialDx™?
Patients with pheochromocytoma, insulinoma, or a history of hypersensitivity to glucagon should avoid using this medication.
Is Gvoke VialDx™ suitable for pediatric patients?
No, the safety and effectiveness of Gvoke VialDx have not been established for pediatric use as a diagnostic aid.
